Do glutamatergic agents represent a new class of antidepressant drugs? Part 2

Journal of Clinical Psychiatry

Volumn 70, Issue 11, 2009, Pages 1604-1605

  Sanacora, Gerard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPA RECEPTOR; ANTIDEPRESSANT AGENT; CYCLOSERINE; ESCITALOPRAM; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; IONOTROPIC RECEPTOR; KETAMINE; MAGNESIUM; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RECEPTOR SUBTYPE; TRAXOPRODIL; ZINC;

ALCOHOLISM; BEHAVIOR THERAPY; BRAIN FUNCTION; CLINICAL TRIAL; COGNITION; DEPRESSION; DISEASE SEVERITY; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; MAJOR DEPRESSION; MENTAL DISEASE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PERCEPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; HUMANS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 72849111367     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09ac05757blu     Document Type: Review

References (27)

1. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5(5):405-414. PubMed (Pubitemid 34454245)
2. Ivanov A, Pellegrino C, Rama S, et al. Opposing role of synaptic and extrasynaptic NMDA receptors in regulation of the extracellular signal-regulated kinases (ERK) activity in cultured rat hippocampal neurons. J Physiol. 2006;572(pt 3):789-798. PubMed
3. Crane GE. Cycloserine as an antidepressant agent. Am J Psychiatry. 1959;115(11):1025-1026. PubMed
4. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol. 1999;375(1-3):31-40. PubMed doi:10.1016/S0014-2999(99)00330-1
5. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-354. PubMed doi:10.1016/S0006-3223(99)00230-9 (Pubitemid 30109248)
6. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-864. PubMed doi:10.1001/archpsyc.63.8.856
7. Mathew SJ, Murrough JW, Aan Het Rot M, et al. Riluzole for relapse prevention following intravenous ketamine in treatmentresistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol. 2009;1-12. PubMed doi:10.1017/S1461145709000169
8. Garcia LS, Comim CM, Valvassori SS, et al. Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(3):450-455. PubMed doi:10.1016/j.pnpbp.2009.01.004
9. Yilmaz A, Schulz D, Aksoy A, et al. Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav. 2002;71(1-2):341-344. PubMed doi:10.1016/S0091-3057(01)00693-1
10. Sofia RD, Harakal JJ. Evaluation of ketamine HCl for anti-depressant activity. Arch Int Pharmacodyn Ther. 1975;214(1):68-74. PubMed
11. Preskorn SH, Baker B, Kolluri S, et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2009;29(4):411-412. PubMed doi:10.1097/JCP.0b013e3181afda04
12. Kotermanski SE, Wood JT, Johnson JW. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol. 2009;587(pt 19):4589-4604. PubMed doi:10.1113/jphysiol.2009.176297
13. Zarate CA Jr, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153-155. PubMed doi:10.1176/appi.ajp.163.1.153
14. Muhonen LH, Lönnqvist J, Juva K, et al. Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence. J Clin Psychiatry. 2008;69(3):392-399. PubMed doi:10.4088/JCP.v69n0308 (Pubitemid 351549391)
15. Davis M, Ressler K, Rothbaum BO, et al. Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry. 2006;60(4):369-375. PubMed doi:10.1016/j.biopsych.2006.03.084 (Pubitemid 44215855)
16. Heresco-Levy U, Javitt DC, Gelfin Y, et al. Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord. 2006;93(1-3):239-243. PubMed doi:10.1016/j.jad.2006. 03.004 (Pubitemid 43816064)
17. Norberg MM, Krystal JH, Tolin DF. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry. 2008;63(12):1118-1126. PubMed doi:10.1016/j.biopsych.2008.01.012
18. Morita K, Motoyama N, Kitayama T, et al. Antinociceptive effects of glycine transporter inhibitors in neuropathic pain models in mice. Nippon Yakurigaku Zasshi. 2007;130(6):458-463. PubMed
19. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel. 2009;12(4):468-478. PubMed
20. Malinow R, Malenka RC. AMPA receptor trafficking and synaptic plasticity. Annu Rev Neurosci. 2002;25(1):103-126. PubMed doi:10.1146/annurev.neuro.25. 112701.142758 (Pubitemid 34748013)
21. Kessels HW, Malinow R. Synaptic AMPA receptor plasticity and behavior. Neuron. 2009;61(3):340-350. PubMed doi:10.1016/j.neuron.2009.01.015
22. Bleakman D, Alt A, Witkin JM. AMPA receptors in the therapeutic management of depression. CNS Neurol Disord Drug Targets. 2007;6(2):117-126. PubMed doi:10.2174/187152707780363258 (Pubitemid 46681772)
23. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry. 2007;164(8):1181-1188. PubMed doi:10.1176/appi.ajp.2007.06111790 (Pubitemid 47292406)
24. Laje G, Paddock S, Manji H, et al. Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry. 2007;164(10):1530-1538. PubMed doi:10.1176/appi.ajp.2007.06122018 (Pubitemid 350069732)
25. Du J, Suzuki K, Wei Y, et al. The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology. 2007;32(4):793-802. PubMed doi:10.1038/sj.npp.1301178 (Pubitemid 46426179)
26. Maeng S, Zarate CA Jr, Du J, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino- 3-hydroxy-5- methylisoxazole-4-propionic acid receptors. Biol Psychiatry. 2008;63(4):349-352. PubMed doi:10.1016/j.biopsych.2007.05.028 (Pubitemid 351146651)
27. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull. 1994;30(4):533-540. PubMed